A new era of targeting cystic fibrosis with non-viral delivery of genomic medicines

Adv Drug Deliv Rev. 2024 Apr 14:115305. doi: 10.1016/j.addr.2024.115305. Online ahead of print.ABSTRACTCystic fibrosis (CF) is a complex genetic respiratory disorder that necessitates innovative gene delivery strategies to address the mutations in the gene. This review delves into the promises and challenges of non-viral gene delivery for CF therapy and explores strategies to overcome these hurdles. Several emerging technologies and nucleic acid cargos for CF gene therapy are discussed. Novel formulation approaches including lipid and polymeric nanoparticles promise enhanced delivery through the CF mucus barrier, augmenting the potential of non-viral strategies. Additionally, safety considerations and regulatory perspectives play a crucial role in navigating the path toward clinical translation of gene therapy.PMID:38626860 | DOI:10.1016/j.addr.2024.115305
Source: Advanced Drug Delivery Reviews - Category: Drugs & Pharmacology Authors: Source Type: research